ClinicalTrials.gg
CompletedNCT03311906Updated Mar 5, 2018

Evaluation of the Efficacy of 0.8% Hyaluronic Acid Gel

A Phase 4 interventional study of 0.8% Hyaluronic Acid and Scaling and Root Planing in Periodontitis, sponsored by Riyadh Colleges of Dentistry and Pharmacy. Completed at 1 site in Saudi Arabia. Per ClinicalTrials.gov, last updated 2018-03-05.

Sponsored by Riyadh Colleges of Dentistry and Pharmacy · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2017, 9 years 3 months ago, and no results have been posted to the registry.
  • Registered 7 months after the study started (first participant enrolled Feb 2017, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Sex
All
01

Study summary

assess the clinical and laboratory effects of the local and sub gingival application of a 0.8% hyaluronic acid gel (GENGIGEL®) as an adjunct to scaling and root planning (SRP) in chronic moderate to severe periodontitis patients as indicated by expression of Human Beta Definsin-2 (HBD2) in gingival crevicular fluid (GCF).

Read the detailed description

Patients who fulfilled the selection criteria will be included in the study. One quadrant will be treated with HA gel (test) and the other without to serve as control. Clinical examination will be done in a dental chair under standard conditions of light, using mouth mirror and graduated Williams Periodontal Probe.

All patients will receive full mouth scaling and root planing with hand instruments and ultrasonic scalers at baseline. Thereafter, in the test quadrant, 1 ml of 0.8% hyaluronic acid gel will be administered subgingivally in all selected test sites at baseline and 1 week later. The following clinical parameters will be recorded at baseline, after 6 weeks and 12 weeks post treatment. Oral hygiene instructions will be given to all patients. The clinical measurements and treatment will be performed by a single examiner.For every patient and control subject, GCF samples will be collected at baseline, 6 weeks and 12 weeks post treatment. The samples will be pooled from two periodontal sites with clinical attachment level of 3 mm or more (in the two different quadrants). The sampling area will be isolated with cotton rolls and carefully will be cleaned supragingivally with sterile cotton pellets. A sterile absorbent paper point will be inserted into the gingival crevice or pocket until resistance will be felt. The paper point will be held in place for 30 s and then will be transferred to a vial containing 100 μL of distilled water and vigorously will be mixed. The paper points will be removed, and the samples will be centrifuged and will be washed twice with distilled water. The resultant pellets will be resuspended in 0.4 mL of distilled water. The samples will be coded and stored at -70 °C until use for ELISA test for identification of Human beta Defensin-2.

02

Conditions studied

  • Periodontitis

Browse trials for

03

In context

Periodontitis

1,239 studies on the registry are indexed under Periodontitis; 302 are open to participants now.

This study's enrollment of 24 is below the median of 44 across 848 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Riyadh Colleges of Dentistry and Pharmacy is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients should be systemically healthy with moderate to severe chronic periodontitis of more than 4 mm probing depth in at least two sites in different quadrants.
  • Patient should exhibit no known allergies
  • Participants should have the ability to attend the hospital regular intervals.

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • nursing
  • hypertension
  • patient with chronic diseases such as diabetes mellitus or rheumatoid arthritis. -Participants should not be under antibiotics and\or had receive any periodontal therapy for the last 6 months.
  • Participants should not taking drugs that could affect the state of the gingival tissues.
  • Participants must not be undergoing orthodontic therapy, caries free
  • Participants must not be using any other supplemental plaque control measures like mouthwashes.
  • Participants should not have the habit of taking alcohol, smoking or chewing tobacco and do not suffer from any systemic disease.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Test side

    Scaling and Root Planing 0.8% Hyaluronic acid gel

    Drug: 0.8% Hyaluronic Acid · Procedure: Scaling and Root Planing

  • Active comparator
    Control Side

    Scaling and Root Planing

    Procedure: Scaling and Root Planing

Interventions

  • Application of 0.8% hyaluronic acid after scaling and root planing

    Also known as: Gengigel

  • ProcedureScaling and Root Planing

    Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes

06

What researchers measure

Primary outcomes

  1. Clinical Attachment Level (CAL) change

    Distance from the cementoenamel junction to the base of gingival sulcus using a UNC15 probe

    Time frame: baseline, six weeks, 12 weeks

  2. Probing Depth change

    It's the distance from the gingival margin to base of the sulcus

    Time frame: baseline, six weeks, 12 weeks

  3. Gingival Index change (Loe and Silness, 1963)

    To assess the gingival condition and record qualitative chances in the gingiva

    Time frame: baseline, six weeks, 12 weeks

  4. Plaque index change (Loe and Silness, 1964)

    To measure the state of oral hygiene

    Time frame: baseline, six weeks, 12 weeks

  5. Papillary Bleeding Index change (Muhlemann, 1977)

    immediate evaluation of the patient's gingival motivation and condition

    Time frame: baseline, six weeks, 12 weeks

Secondary outcomes

  1. HBD-2 change

    By take gingival crevicular fluid sample elisa test

    Time frame: baseline, six weeks, 12 weeks

07

Study locations

1 site
  • Riyadh Colleges of Dentistry and Pharmacy
    Riyadh, AlRiyadh 11681, Saudi Arabia
08

References and documents

Publications

  • Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005 Mar;3(3):238-50. doi: 10.1038/nrmicro1098. PubMed 15703760 ↗
  • Diamond DL, Kimball JR, Krisanaprakornkit S, Ganz T, Dale BA. Detection of beta-defensins secreted by human oral epithelial cells. J Immunol Methods. 2001 Oct 1;256(1-2):65-76. doi: 10.1016/s0022-1759(01)00442-2. PubMed 11516756 ↗
  • Embery G, Waddington RJ, Hall RC, Last KS. Connective tissue elements as diagnostic aids in periodontology. Periodontol 2000. 2000 Oct;24:193-214. doi: 10.1034/j.1600-0757.2000.2240109.x. No abstract available. PubMed 11276867 ↗
  • Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U, Adermann K, Kluver E, Vogelmeier C, Becker D, Hedrich R, Forssmann WG, Bals R. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 2001 Nov;306(2):257-64. doi: 10.1007/s004410100433. PubMed 11702237 ↗
  • Gontiya G, Galgali SR. Effect of hyaluronan on periodontitis: A clinical and histological study. J Indian Soc Periodontol. 2012 Apr;16(2):184-92. doi: 10.4103/0972-124X.99260. PubMed 23055583 ↗
  • Gorr SU. Antimicrobial peptides in periodontal innate defense. Front Oral Biol. 2012;15:84-98. doi: 10.1159/000329673. Epub 2011 Nov 11. PubMed 22142958 ↗
  • Gorr SU, Abdolhosseini M. Antimicrobial peptides and periodontal disease. J Clin Periodontol. 2011 Mar;38 Suppl 11:126-41. doi: 10.1111/j.1600-051X.2010.01664.x. PubMed 21323710 ↗
  • Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. Periodontol 2000. 1994 Jun;5:78-111. doi: 10.1111/j.1600-0757.1994.tb00020.x. No abstract available. PubMed 9673164 ↗
  • Heitz-Mayfield LJ. How effective is surgical therapy compared with nonsurgical debridement? Periodontol 2000. 2005;37:72-87. doi: 10.1111/j.1600-0757.2004.03797.x. No abstract available. PubMed 15655026 ↗
  • Jentsch H, Pomowski R, Kundt G, Gocke R. Treatment of gingivitis with hyaluronan. J Clin Periodontol. 2003 Feb;30(2):159-64. doi: 10.1034/j.1600-051x.2003.300203.x. PubMed 12622859 ↗
  • Johannsen A, Tellefsen M, Wikesjo U, Johannsen G. Local delivery of hyaluronan as an adjunct to scaling and root planing in the treatment of chronic periodontitis. J Periodontol. 2009 Sep;80(9):1493-7. doi: 10.1902/jop.2009.090128. PubMed 19722800 ↗
  • Loe H. The Gingival Index, the Plaque Index and the Retention Index Systems. J Periodontol. 1967 Nov-Dec;38(6):Suppl:610-6. doi: 10.1902/jop.1967.38.6.610. No abstract available. PubMed 5237684 ↗
  • LOE H, SILNESS J. PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand. 1963 Dec;21:533-51. doi: 10.3109/00016356309011240. No abstract available. PubMed 14121956 ↗
  • Moseley R, Waddington RJ, Embery G. Hyaluronan and its potential role in periodontal healing. Dent Update. 2002 Apr;29(3):144-8. doi: 10.12968/denu.2002.29.3.144. PubMed 11989392 ↗
  • Muhlemann HR. Psychological and chemical mediators of gingival health. J Prev Dent. 1977 Jul-Aug;4(4):6-17. No abstract available. PubMed 275483 ↗
  • Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, Nagaoka I, Okumura K, Ogawa H. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol. 2007 Mar;127(3):594-604. doi: 10.1038/sj.jid.5700599. Epub 2006 Oct 19. PubMed 17068477 ↗
  • Pereira AL, Franco GC, Cortelli SC, Aquino DR, Costa FO, Raslan SA, Cortelli JR. Influence of periodontal status and periodontopathogens on levels of oral human beta-defensin-2 in saliva. J Periodontol. 2013 Oct;84(10):1445-53. doi: 10.1902/jop.2012.120321. Epub 2012 Nov 23. PubMed 23173827 ↗
  • Pilloni A, Annibali S, Dominici F, Di Paolo C, Papa M, Cassini MA, Polimeni A. Evaluation of the efficacy of an hyaluronic acid-based biogel on periodontal clinical parameters. A randomized-controlled clinical pilot study. Ann Stomatol (Roma). 2011 Mar;2(3-4):3-9. Epub 2012 Jan 27. PubMed 22545183 ↗
  • Pirnazar P, Wolinsky L, Nachnani S, Haake S, Pilloni A, Bernard GW. Bacteriostatic effects of hyaluronic acid. J Periodontol. 1999 Apr;70(4):370-4. doi: 10.1902/jop.1999.70.4.370. PubMed 10328647 ↗
  • Polepalle T, Srinivas M, Swamy N, Aluru S, Chakrapani S, Chowdary BA. Local delivery of hyaluronan 0.8% as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A clinical and microbiological study. J Indian Soc Periodontol. 2015 Jan-Feb;19(1):37-42. doi: 10.4103/0972-124X.145807. PubMed 25810591 ↗
  • Porter EM, Liu L, Oren A, Anton PA, Ganz T. Localization of human intestinal defensin 5 in Paneth cell granules. Infect Immun. 1997 Jun;65(6):2389-95. doi: 10.1128/iai.65.6.2389-2395.1997. PubMed 9169779 ↗
  • Xu Y, Hofling K, Fimmers R, Frentzen M, Jervoe-Storm PM. Clinical and microbiological effects of topical subgingival application of hyaluronic acid gel adjunctive to scaling and root planing in the treatment of chronic periodontitis. J Periodontol. 2004 Aug;75(8):1114-8. doi: 10.1902/jop.2004.75.8.1114. PubMed 15455740 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Aug 2017, 6 months.

Of 29 non-industry phase 4 interventional studies under Periodontitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 6 months is below that.

Counting every sponsor, half of 30 studies reached it within 11 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 17, 2017
StartActual
Feb 15, 2017
Primary completionActual
Aug 15, 2017
CompletionActual
Oct 2, 2017
Last update
Mar 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03311906
Lead sponsor
Riyadh Colleges of Dentistry and Pharmacy
Responsible party
Nour Al Shammari (Senior Resident, Riyadh Colleges of Dentistry and Pharmacy) — Principal investigator
First posted
Oct 17, 2017
Start date
Feb 15, 2017
Primary completion
Aug 15, 2017
Completion
Oct 2, 2017
Last update
Mar 5, 2018

Study contacts

Sanaa M Shafshak, PhD
study director · Riyadh Colleges of Dentistry and Pharmacy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion